Comparison Overview

HEADLINE PUBLISHING GROUP

VS

The Center for Biosimilars

HEADLINE PUBLISHING GROUP

CARMELITE HOUSE 50 VICTORIA EMBANKMENT, LONDON, EC4Y 0DZ, GB
Last Update: 2025-11-26
View Profile
Between 750 and 799
https://www.headline.co.uk/

Headline is part of Hachette UK, one of the UK’s biggest publishing groups. We publish a wide range of fiction and non-fiction titles and are renowned for passion, quality and delivering bestselling commercial books in many different formats. Headline has spent over three decades creating books people want to read and our passion for the commercial means we are home to some of the UK’s biggest-selling authors and continue to invest in new talent with bestseller potential. Our nimble attitude towards the social reading era has allowed us to be playful with format as never before and create digital bestsellers. Our spirit of entertainment thrives in a world where direct communication means we can talk to readers, booksellers and reviewers to show and spread our love for books, at the touch of a button. Headline will always represent a modern mindset and an energetic outlook. And always stand for best-in-class publishing.

NAICS: 511
NAICS Definition:
Employees: 79
Subsidiaries: 15
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

The Center for Biosimilars

undefined, Cranbury, NJ, undefined, undefined
Last Update: 2025-11-26
Between 700 and 749
http://www.centerforbiosimilars.com

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

NAICS: 511
NAICS Definition:
Employees: 2
Subsidiaries: 57
12-month incidents
0
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/headline-publishing-group-limited.jpeg
HEADLINE PUBLISHING GROUP
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/thecenterforbiosimilars.jpeg
The Center for Biosimilars
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
HEADLINE PUBLISHING GROUP
100%
Compliance Rate
0/4 Standards Verified
The Center for Biosimilars
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for HEADLINE PUBLISHING GROUP in 2025.

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for The Center for Biosimilars in 2025.

Incident History — HEADLINE PUBLISHING GROUP (X = Date, Y = Severity)

HEADLINE PUBLISHING GROUP cyber incidents detection timeline including parent company and subsidiaries

Incident History — The Center for Biosimilars (X = Date, Y = Severity)

The Center for Biosimilars cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/headline-publishing-group-limited.jpeg
HEADLINE PUBLISHING GROUP
Incidents

No Incident

https://images.rankiteo.com/companyimages/thecenterforbiosimilars.jpeg
The Center for Biosimilars
Incidents

Date Detected: 08/2022
Type:Cyber Attack
Blog: Blog

Date Detected: 5/2018
Type:Breach
Attack Vector: Unauthorized Access
Blog: Blog

FAQ

HEADLINE PUBLISHING GROUP company demonstrates a stronger AI Cybersecurity Score compared to The Center for Biosimilars company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

The Center for Biosimilars company has historically faced a number of disclosed cyber incidents, whereas HEADLINE PUBLISHING GROUP company has not reported any.

In the current year, The Center for Biosimilars company and HEADLINE PUBLISHING GROUP company have not reported any cyber incidents.

Neither The Center for Biosimilars company nor HEADLINE PUBLISHING GROUP company has reported experiencing a ransomware attack publicly.

The Center for Biosimilars company has disclosed at least one data breach, while HEADLINE PUBLISHING GROUP company has not reported such incidents publicly.

The Center for Biosimilars company has reported targeted cyberattacks, while HEADLINE PUBLISHING GROUP company has not reported such incidents publicly.

Neither HEADLINE PUBLISHING GROUP company nor The Center for Biosimilars company has reported experiencing or disclosing vulnerabilities publicly.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds any compliance certifications.

Neither company holds any compliance certifications.

The Center for Biosimilars company has more subsidiaries worldwide compared to HEADLINE PUBLISHING GROUP company.

HEADLINE PUBLISHING GROUP company employs more people globally than The Center for Biosimilars company, reflecting its scale as a Book and Periodical Publishing.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds SOC 2 Type 1 certification.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds SOC 2 Type 2 certification.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds ISO 27001 certification.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds PCI DSS certification.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds HIPAA certification.

Neither HEADLINE PUBLISHING GROUP nor The Center for Biosimilars holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

ThingsBoard in versions prior to v4.2.1 allows an authenticated user to upload malicious SVG images via the "Image Gallery", leading to a Stored Cross-Site Scripting (XSS) vulnerability. The exploit can be triggered when any user accesses the public API endpoint of the malicious SVG images, or if the malicious images are embedded in an `iframe` element, during a widget creation, deployed to any page of the platform (e.g., dashboards), and accessed during normal operations. The vulnerability resides in the `ImageController`, which fails to restrict the execution of JavaScript code when an image is loaded by the user's browser. This vulnerability can lead to the execution of malicious code in the context of other users' sessions, potentially compromising their accounts and allowing unauthorized actions.

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss4
Base: 6.2
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to to verify that the token used during the code exchange originates from the same authentication flow, which allows an authenticated user to perform account takeover via a specially crafted email address used when switching authentication methods and sending a request to the /users/login/sso/code-exchange endpoint. The vulnerability requires ExperimentalEnableAuthenticationTransfer to be enabled (default: enabled) and RequireEmailVerification to be disabled (default: disabled).

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss3
Base: 9.9
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H
References
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to sanitize team email addresses to be visible only to Team Admins, which allows any authenticated user to view team email addresses via the GET /api/v4/channels/{channel_id}/common_teams endpoint

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

Exposure of email service credentials to users without administrative rights in Devolutions Server.This issue affects Devolutions Server: before 2025.2.21, before 2025.3.9.

Published
Date
2025-11-27
Updated
Date
2025-11-27
References
Description

Exposure of credentials in unintended requests in Devolutions Server.This issue affects Server: through 2025.2.20, through 2025.3.8.

Published
Date
2025-11-27
Updated
Date
2025-11-27
References